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EDITORIAL
From heart to bad sleep----Lessons for sleep apnoea in times
of crisisa
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Obstructive sleep apnoea syndrome (OSAS) is a largely
prevalent disorder characterized by repeated episodes of
pharyngeal obstruction that causes oxygen desaturation and
sleep fragmentation. Besides the consequences of exces-
sive daytime sleepiness including increased risk of trafﬁc
and labour accidents, OSAS has been implicated, with great
or less evidence, as an independent risk factor for differ-
ent cardiovascular diseases as hypertension, stroke, heart
failure, arrhythmias, coronary heart disease and myocardial
infarction.1 The recognition of OSAS as a treatable puta-
tive cause of hypertension and the need for screening is
present in international recommendations since 2003.2 Sev-
eral studies have found an association between OSAS and
coronary artery heart disease (CAD). In a large prospective
longitudinal study in men and women who were free of CAD
at baseline and followed for 8.7 years, after adjustment
for multiple risk factors, OSAS was positively associated to
myocardial infarction, revascularization procedure or death
only in men aged <70 years old (adjusted ratio 1.10 [95%
CI 1.00, 1.21] per 10-unit increase in apnoea--hypopnea
index), but not in older men or in women of any age.3 Other
studies showed that patients suffering from CAD with an
AHI greater than 10 events/hour were more prone to die
in 5-year follow-up than patients without OSAS (37.5% vs.
9.3%, respectively) after controlling for age, weight, and
smoking.4,5 On the other hand in patients with CAD that
had percutaneous intervention the probability of resteno-
sis, vessel remodelling and cardiac mortality was greater in
the presence of OSAS.6,7 Moreover patients with CAD treated
with CPAP had better prognosis than those who were not
treated.8--11
So, it appears rational to establish strategies to search
for OSAS in patients with a diagnosis of CAD. In this issue of
RPP, Areias et al.12 contribute to this purpose: using a level
IV equipment (ApneaLinkTM, a two-channel device that mon-
itores respiratory ﬂow and O2 saturation) they were able to
detect the presence of OSAS, conﬁrmed by polysomnogra-
phy, in 43% of patients admitted to ICU for acute coronary
syndrome. These results are not much different from other
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tudies using different methodologies, that together point
o a much greater prevalence in CAD than the admitted for
eneral population.13,14 Independently of some issues that
eed to be clariﬁed, as the better methodology and time of
creening, these date reinforce the importance of detecting
SAS in CAD patients.
OSAS is a treatable condition and the ﬁrst line treat-
ent is ventilation with continuous positive airway pressure
CPAP); the main challenge of this form of treatment is
atient adherence. It is known that multiple factors inter-
ere in this matter that involves individual characteristics
including the symptomatic state, e.g. hypersomnolence but
lso personality proﬁle), education and literacy, iatrogenic-
ty, marital support, health care support or reimbursement
olicies. In this issue of RPP Mota et al.15 report an inter-
sting ﬁnding of insomnia complaints after the initiation of
PAP treatment for OSAS. Despite some caveats of the study,
ainly in psychological characterization of these patients
r the timing of appearance and the duration of the symp-
oms, in our knowledge this is the ﬁrst paper that gives
ata on a form of adjustment insomnia that, in this study,
ppeared to be related to tolerance to CPAP pressure.
he association of insomnia to OSAS, in some instances,
s already known and can be related to the presence of
sychological disturbances16,17 or to be a manifestation of
SAS in and of itself. In the latter case we can expect
hat treating the respiratory problem solves insomnia and,
n fact, in the present study by Mota et al., almost half
he patients (11/24) with pre-existing insomnia showed
esolution of this problem after initiation of CPAP. Nev-
rtheless, is also known that insomnia complaints have a
ajor impact on adherence to treatment18,19 and that a spe-
iﬁc approach should be offered to deal with this problem
hich underline the importance of multidisciplinary to sleep
edicine.
In summary, two articles in this issue of RPP12,15 express
wo important factors in OSAS: one is the necessity to screen
atients with cardiovascular disease for OSAS in order to
reat them and reduce the risk of serious co-morbidities
gia. Published by Elsevier España, S.L. All rights reserved.
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2nd, second, is the difﬁculty in resolving speciﬁc problems
o assure proper treatment adherence.
OSAS has become an important ﬁnancial burden to the
ational Health Service costs: the annual expenses for domi-
iliary respiratory care amount to 55.5 millions euros/year
nd, according to data from ACSS, OSAS treatment accounts
or more than 50% of that cost20 As is estimated that only
0% of the patients with OSAS in Portugal are diagnosed
nd treated20 an exponential increase in costs is foresee-
ble, particularly if the platform of patient recruitment is
idened to include not only patients with ‘‘classic’’ symp-
oms but also refractory hypertension or CAD as is pointed
y the study of Areias et al.12 In order to reduce the ﬁnancial
mpact the Government has published, for public discussion,
uidelines in domiciliary respiratory care that attempt to
uarantee that OSAS treatment is provided based on speciﬁc
iagnostic criteria (not difﬁcult) but also assuming that the
ayment for treatment be assured only if patient is adher-
nt and stipulating a 6-month ‘‘experimental period’’ (sic).
ven if the principle is correct -- payment conditioned by
dherence -- there are multiple causes for non-adherence
as, for instance, that showed in the study by Mota et al.15)
hat deserve speciﬁc treatment approaches and the resolu-
ion of which may need longer time frames than the 6-month
eriod admitted in the government proposal. Moreover, if
t is true that short-term adherence can predict long-term
dherence, difﬁculties in treatment compliance may arise at
ny time and for different reasons. In our experience, only
--3% of patient refuse, deﬁnitively, treatment with CPAP;
bout 20% present other reasons for adherence below the
tipulated as effective and these patients are at risk of hav-
ng their CPAP payment withdrawn, increasing the burden of
he disease due to co-morbidities that could be prevented
ith the treatment. So, the governmental desire to avoid
aste in costs should be calibrated to assure that the patient
s offered all solutions necessary to improve adherence and
his is, frequently, a task for a multidisciplinary health team
ased in a reference sleep center. In other words, treat-
ent suspension, even in a situation of refusal, should be a
edical decision rather than a burocratic one.
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